nafamostat has been researched along with Viral Diseases in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nafamostat has been shown to have other, immunomodulatory effects, which may be beneficial for treatment, however animal models of ssRNA virus infection are lacking." | 5.72 | Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness. ( Anthony, DC; Dunstan, IK; Strekalova, T; Weglinski, CM; Yates, AG; Ying, Y, 2022) |
| "Nafamostat has been shown to have other, immunomodulatory effects, which may be beneficial for treatment, however animal models of ssRNA virus infection are lacking." | 1.72 | Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness. ( Anthony, DC; Dunstan, IK; Strekalova, T; Weglinski, CM; Yates, AG; Ying, Y, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yates, AG | 1 |
| Weglinski, CM | 1 |
| Ying, Y | 1 |
| Dunstan, IK | 1 |
| Strekalova, T | 1 |
| Anthony, DC | 1 |
1 other study available for nafamostat and Viral Diseases
| Article | Year |
|---|---|
Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness.
Topics: Animals; Benzamidines; COVID-19; COVID-19 Drug Treatment; Guanidines; Illness Behavior; Imidazoles; | 2022 |